2. Academic Validation
  3. Apelin-13 alleviates osteoclast formation and osteolysis through Nrf2-pyroptosis pathway

Apelin-13 alleviates osteoclast formation and osteolysis through Nrf2-pyroptosis pathway

  • Microsc Res Tech. 2024 Feb 21. doi: 10.1002/jemt.24519.
Zhaoyang Yin 1,  Qinghua Cheng 2,  Chao Wang 3,  Qin Hu 3,  Jian Yin 3,  Bin Wang 3
Affiliations

Affiliations

  • 1 Department of Orthopedics, The Affiliated Lianyungang Hospital of Xuzhou Medical University (The First People's Hospital of Lianyungang), Lianyungang, China.
  • 2 Department of Orthopedics, Nanjing Lishui People's Hospital, Zhongda Hospital Lishui Branch, Southeast University, Nanjing, China.
  • 3 Department of Orthopedics, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, China.
PMID: 38380581 DOI: 10.1002/jemt.24519
Abstract

Wear particle-induced periprosthetic osteolysis is the key to aseptic loosening after artificial joint replacement. Osteoclastogenesis plays a central role in this process. Apelin-13 is a member of the adipokine family with anti-inflammatory effects. Here, we report that apelin-13 alleviates RANKL-mediated osteoclast differentiation and titanium particle-induced osteolysis in mouse calvaria. Mechanistically, apelin-13 inhibits NLRP3 inflammasome-mediated Pyroptosis by activating the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway. In summary, apelin-13 is expected to be a potential drug for relieving aseptic osteolysis. RESEARCH HIGHLIGHTS: This study reveals the molecular mechanism by which apelin-13 inhibits NLRP3 inflammasome activation and Pyroptosis by promoting Nrf2. This study confirms that apelin-13 alleviates osteoclast activation by inhibiting Pyroptosis. In vivo studies further confirmed that apelin-13 alleviated mouse skull osteolysis by inhibiting the activation of NLRP3 inflammasome.

Keywords

NLRP3; Nrf2; apelin-13; periprosthetic osteolysis; pyroptosis.

Figures
Products